Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of the IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus in Patients With Relapsed/Refractory Multiple Myeloma

NCT01234974 is registered in ClinicalTrials.gov with Milton S. Hershey Medical Center as lead sponsor.

NCT NCT01234974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01234974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of the IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Milton S. Hershey Medical Center
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2010
Completion date
December 31, 2013
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma